KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Receivables: 2009-2024

Historic Change in Receivables for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $74.2 million.

  • Halozyme Therapeutics' Change in Receivables fell 58.30% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.3 million, marking a year-over-year decrease of 11.88%. This contributed to the annual value of $74.2 million for FY2024, which is 2123.57% up from last year.
  • As of FY2024, Halozyme Therapeutics' Change in Receivables stood at $74.2 million, which was up 2,123.57% from $3.3 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Change in Receivables ranged from a high of $83.9 million in FY2022 and a low of -$6.8 million during FY2021.
  • Its 3-year average for Change in Receivables is $53.8 million, with a median of $74.2 million in 2024.
  • Its Change in Receivables has fluctuated over the past 5 years, first plummeted by 117.64% in 2021, then spiked by 2,123.57% in 2024.
  • Over the past 5 years, Halozyme Therapeutics' Change in Receivables (Yearly) stood at $38.3 million in 2020, then tumbled by 117.64% to -$6.8 million in 2021, then soared by 1,342.65% to $83.9 million in 2022, then crashed by 96.02% to $3.3 million in 2023, then spiked by 2,123.57% to $74.2 million in 2024.